Search
for
Sort by
Research 61–90 of 1000+
- Hair, Hormones, and High-Risk Prostate Cancer
- Editorial comment
- Milestones in Photocarcinogenesis
- Prostate cancer risk and recurrence: the role of nutrition and clinical aspects
- Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies
- Next-Gen Therapeutics for Skin Cancer: Nutraceuticals
- Male alopecia, finasteride, and cancer risk
- Equivalent chemotherapy efficacy against leukemia in mice treated with topical vasoconstrictors to prevent cancer therapy side effects
- The <i>BJUI</i>'s clinical trials initiative
- A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
- Proscar and Propecia—A Therapeutic Perspective
- Effects of Short-Term Finasteride on Apoptotic Factors and Androgen Receptors in Prostate Cancer Cells
- Abstract SS02-02: Chemoprevention: Poised for Success
- Chemoprevention – History and general principles
- Editorial comment 1
- PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice
- Finasteride chemoprevention might be cost-effective in high-risk populations
- Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model
- Level-1 Data From the REDUCE Study and the PCPT Data
- Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
- Clinical Pearls in Men's Health
- Provenge is Talk of GU Malignancies Congress
- Field Cancerization: From Molecular Basis to Selective Field-Directed Management of Actinic Keratosis
- Moving Chemoprevention Forward into the Most Promising Areas of Study
- Hot Stuff: Thermal Imaging Aids in Cellulitis Diagnosis
- Side effects of androgen deprivation therapy: monitoring and minimizing toxicity
- Treatment of chemotherapy-induced alopecia
- Finasteride en el año 2006
- Editorial Comment
- Editorial Comment